![Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00272/article_deploy/html/images/pharmaceuticals-14-00272-g001.png)
Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
![IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway](https://www.mdpi.com/ijms/ijms-21-00957/article_deploy/html/images/ijms-21-00957-g003.png)
IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=f57dbebf-f145-4e3c-bfef-b7907f6e01eb-02.jpg&id=554031)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959
![Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/go/2020/go.2020.6/jgo.19.00331/20200328/images/large/jgo.19.00331t3.jpeg)
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology
![Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-020-0171-1/MediaObjects/41523_2020_171_Fig1_HTML.png)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
![Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine](https://www.pppmag.com/files/article-images/ppp_2202_onc_patientsafety_figure.jpg)
Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine
![Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice](https://www.prescribingpractice.com/media/bp5fx5du/calculation_16_1000x667.jpg)
Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice
![Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy](https://www.cell.com/cms/attachment/cd22f0c8-1524-4c03-b666-7a80d91c712d/gr1_lrg.jpg)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy
![Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion](https://www.prescribingpractice.com/media/qi5p2ayx/jprp-2022-4-8-342_f01.jpg)
Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-08.jpg&id=515396)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/asset/9128c19c-393e-4e3e-90aa-ce3b3f824fc5/ga1.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine](https://lupus.bmj.com/content/lupusscimed/9/1/e000779/F1.large.jpg)
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine
![Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41409-022-01908-y/MediaObjects/41409_2022_1908_Fig1_HTML.png)